Therma Bright Inc V.THRM

Alternate Symbol(s): TBRIF

Healthcare Medical Devices

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.

TSXV:THRM - Post by User

Therma Bright Inc > To All Pumpers 🤡

<< Previous

Bullboard Posts

Next >>

Comment by Vincenzovegaon May 13, 2022 1:35pm

98 Views

Post# 34682237

RE:RE:RE:RE:To All Pumpers 🤡

Smokey1958 wrote:
Vinny, kudos to you for still putting up with these clowns who consistently express baseless drivel without any evidence to support their claims. Yes, investing in stocks is no easy finacial strategy these days but even these clowns make a mockery of DD, rational thought and risk tolerance.

The following is a complete scientific study carried out on the reliability of Morningstar. It should not be an exclusive tool for DD but it is a sound piece of the puzzle.

https://academyfinancial.org/resources/Documents/Proceedings/2015/C2_Bolster.pdf

These results provide evidence that the Morningstar stock rating system does allow an investor to build a portfolio that outperforms the market average over a long period of time. The results are not as strong after adjusting for portfolio risk, but there is still some evidence of outperformance on a risk-adjusted basis. The risk factors also vary across the different portfolios and the results exhibit some variation over time. It should also be noted that the investment strategies examined herein required a significant amount of trading activity and therefore would incur transactions costs. We show that a modest transaction cost will reduce, but not eliminate, the benefits available from a trading strategy based on the ranking system.

Overall, the results are consistent with Morningstar analysts providing some valuable analysis. They should be of interest to both institutional and individual investors seeking to develop an active, or alpha-generating, investment strategy, to those interested in an unbiased and scientific analysis of this Morningstar service, and to those interested in studies of the impact of analysts’ recommendations.

I would only add that the 1-star price is now described as a (fluid) valuation of the point at which a stock is significantly overvalued and overbought. When the sp is considered extremely undervalued based on the Fair Value sp, as THRM is currently, and the trading volumes are extremely low relative to the no. of outstanding shares, the 1-star does seem to get quite skewed.

Cheers, GLTY and GLTE holding patiently ...it has been quite the ride!!!

Vincenzovega wrote:

Moemoney42 wrote:

Lockdown2020 wrote: Please STOP Sugar coating this stock.
Morning Star is Horse shittt.
Its pretty much over.Even if they get FDA APPROVAL it will only go up minimal.
IMHO

Agreed 2020.. if it pops on the appoval that will give those with money tied up here a chance to exit with possibly getting some of their losses back.. nothing more.. stick a fork in it.. its done.. ;-)

Sorry I believe in Morningstar more than dumb and dumber
IMHO